Hereditary Angioedema Market Global Analysis 2017 Global Hereditary Angioedema Market Size, Trends & | Page 2

Hereditary Angioedema Market Size, Application, Regional Outlook,
Competitive Strategies and Forecasts, 2017 to 2021
Hereditary Angioedema Market is projected to increase at a healthy rate during the forecasted period
(2017-2021). This growth is expected on account of many growth drivers such as increased diagnosis in the
US and Europe, advantages of preventive therapy, approval of Berinert for pediatric treatment, launch of
Haegarda C1 inhibitor and some other major products in the pipeline.
Company Coverage: Shire Plc,iBio,Inc.,Pharming Group NV,CSL Limited.
Hereditary angioedema (HAE) is defined as a condition highlighted by frequent incidences of severe
swelling. It is a rarely inherited disorder. It most commonly affects limbs, face, intestinal and respiratory
tract and causes severe swelling in these parts of the body. Low levels of C1 inhibitor, a protein leads to the
over activation of bradykinin. Bradykinin is a chemical which is the prime cause the occurrence of
angioedema.
Angioedema can be defined as a disorder in which there is a rapid inflammation of the dermis,
subcutaneous tissue, mucosa (cavities surrounding internal organs) and sub mucosal tissues. Angioedema
can further be divided into acquired and hereditary angioedema. Acquired angioedema is generally caused
due to allergy. On the other hand, hereditary angioedema is caused due to genetic mutation.
However, the market also faces certain challenges such as high prophylaxis cost, side effects of Cinryze and
long term prophylactic treatment. Oral therapy for hereditary angioedema attacks and SHP643 monoclonal
antibody are some of the trends in the global hereditary angioedema market.
Complete report available at http://www.marketreportsonline.com/584779.html